Amy Gelfand, AHS 2021: Highlights
It was a great pleasure to meet with Amy Gelfand (University of California, San Francisco, CA, USA) to discuss some of the highlights from this years AHS Meeting.
- What are some of the highlights from this year’s AHS Annual Meeting?
Useful resources: WOLFF Award Winner: Ryotaro Ishii et al., Headache. Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency
Disclosures: Amy Gelfand has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021.
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!